|
AU744636B2
(en)
*
|
1997-09-29 |
2002-02-28 |
Meiji Seika Pharma Co., Ltd. |
Tricyclic triazolobenzazepine derivatives, process for producing the same, and antiallergic
|
|
US7919109B2
(en)
*
|
1999-02-08 |
2011-04-05 |
Intarcia Therapeutics, Inc. |
Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicles
|
|
US7258869B1
(en)
|
1999-02-08 |
2007-08-21 |
Alza Corporation |
Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicle
|
|
ATE410427T1
(de)
|
2001-12-26 |
2008-10-15 |
Meiji Seika Kaisha |
Neues kristallines tricyclisches triazolobenzazepinderivat
|
|
WO2003066634A1
(en)
*
|
2002-02-07 |
2003-08-14 |
Neurogen Corporation |
Substituted fused pyrazolecarboxylic acid arylamides and related compounds
|
|
US7731947B2
(en)
|
2003-11-17 |
2010-06-08 |
Intarcia Therapeutics, Inc. |
Composition and dosage form comprising an interferon particle formulation and suspending vehicle
|
|
NZ551370A
(en)
|
2004-05-14 |
2009-08-28 |
Millennium Pharm Inc |
Compounds and methods for inhibiting mitotic progression by inhibiting of aurora kinase
|
|
US11246913B2
(en)
|
2005-02-03 |
2022-02-15 |
Intarcia Therapeutics, Inc. |
Suspension formulation comprising an insulinotropic peptide
|
|
WO2006083761A2
(en)
|
2005-02-03 |
2006-08-10 |
Alza Corporation |
Solvent/polymer solutions as suspension vehicles
|
|
WO2007140416A2
(en)
|
2006-05-30 |
2007-12-06 |
Intarcia Therapeutics, Inc. |
Two-piece, internal-channel osmotic delivery system flow modulator
|
|
JP5048773B2
(ja)
|
2006-08-09 |
2012-10-17 |
インターシア セラピューティクス，インコーポレイティド |
浸透圧式デリバリーシステム及びピストンアセンブリー
|
|
CL2007003244A1
(es)
*
|
2006-11-16 |
2008-04-04 |
Millennium Pharm Inc |
Compuestos derivados de pirimido[5,4-d][2]benzazepina; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento del cancer.
|
|
NZ580447A
(en)
|
2007-04-23 |
2011-06-30 |
Intarcia Therapeutics Inc |
Suspension formulations of insulinotropic peptides and uses thereof
|
|
CA2726861C
(en)
|
2008-02-13 |
2014-05-27 |
Intarcia Therapeutics, Inc. |
Devices, formulations, and methods for delivery of multiple beneficial agents
|
|
CA2747326C
(en)
|
2008-12-22 |
2017-05-16 |
Millennium Pharmaceuticals, Inc. |
Combination of aurora kinase inhibitors and anti-cd20 antibodies
|
|
JO3635B1
(ar)
|
2009-05-18 |
2020-08-27 |
Millennium Pharm Inc |
مركبات صيدلانية صلبة وطرق لانتاجها
|
|
RU2753280C2
(ru)
|
2009-09-28 |
2021-08-12 |
Интарсия Терапьютикс, Инк. |
Быстрое достижение и/или прекращение существенной стабильной доставки лекарственного средства
|
|
BR112012020557A8
(pt)
|
2010-02-19 |
2018-01-02 |
Millennium Pharm Inc |
formas cristalinas de 4-{[9-cloro-7-(2-flúor-6-metoifenil)-5h-pirimido[5,4-d][2]benzazepin-2-il]amino}-2-metoxibenzoato de sódio
|
|
US20120208755A1
(en)
|
2011-02-16 |
2012-08-16 |
Intarcia Therapeutics, Inc. |
Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
|
|
US20130303519A1
(en)
|
2012-03-20 |
2013-11-14 |
Millennium Pharmaceuticals, Inc. |
Methods of treating cancer using aurora kinase inhibitors
|
|
CA2907726A1
(en)
|
2013-03-22 |
2014-09-25 |
Millennium Pharmaceuticals, Inc. |
Combination of catalytic mtorc1/2 inhibitors and selective inhibitors of aurora a kinase
|
|
US9889085B1
(en)
|
2014-09-30 |
2018-02-13 |
Intarcia Therapeutics, Inc. |
Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
|
|
ES2968262T3
(es)
|
2015-06-03 |
2024-05-08 |
I2O Therapeutics Inc |
Sistemas de colocación de implantes
|
|
US20180207173A1
(en)
|
2015-07-21 |
2018-07-26 |
Millennium Pharmaceuticals, Inc. |
Administration of aurora kinase inhibitor and chemotherapeutic agents
|
|
CN109310743A
(zh)
|
2016-05-16 |
2019-02-05 |
因塔西亚制药公司 |
胰高血糖素受体选择性多肽及其使用方法
|
|
USD840030S1
(en)
|
2016-06-02 |
2019-02-05 |
Intarcia Therapeutics, Inc. |
Implant placement guide
|
|
USD860451S1
(en)
|
2016-06-02 |
2019-09-17 |
Intarcia Therapeutics, Inc. |
Implant removal tool
|
|
MX2019008006A
(es)
|
2017-01-03 |
2019-08-29 |
Intarcia Therapeutics Inc |
Metodos que comprenden la administracion continua de un agonista del receptor de glp-1 y la co-administracion de un farmaco.
|